Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGF Vaccine in Stage IV NSCLC
NCT02187367Phase 3Terminated
- Sponsor
- Bioven
- Start
- May 2015
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 11
01
Overview
A Phase 3 trial of cimavax egf in non-small cell lung cancer (NSCLC), sponsored by Bioven. Started May 2015; status: terminated.
02
Drugs
cimavax egf
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02187367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02187367.